Dr. James Robert Hoffmann, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3805 W 28th Ave, Pine Bluff, AR 71603 Phone: 870-536-4100 |
Evan N Newbolt, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3805 West 28th Ave, Pine Bluff, AR 71603 Phone: 870-536-4100 Fax: 304-598-6928 |
Paul J. Misischia, D.O. Ophthalmology Medicare: Medicare Enrolled Practice Location: 3805 West 28th Ave., Pine Bluff, AR 71603 Phone: 870-536-4100 Fax: 870-536-9020 |
Dr. David T. Nixon, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1716 W 42nd Ave, Pine Bluff, AR 71603 Phone: 870-534-2624 Fax: 870-534-2630 |
Mr. Michael S Mcfarland, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3805 W 28th Ave, Pine Bluff, AR 71603 Phone: 870-536-4100 Fax: 870-534-3982 |
News Archive
A muscle relaxant called dantrolene used for treating malignant hyperthermia boosts the activity of therapies currently being developed to treat the genetic disorder Duchenne muscular dystrophy (DMD), show study findings.
Valensa International announced today that it has developed technology that has dramatically increased the stability and shelf-life of the powerful, versatile antioxidant astaxanthin. The company has just completed a 7-year shelf-life study of its Zanthin(R) natural astaxanthin that indicates that this ultra-high pressure supercritical CO2 extract of Haematococcus pluvialis, bolstered by Valensa's proprietary O2B(R) Peroxidation Blocker technology, has a minimum 4-year shelf-life.
Fragments of cancer DNA circulating in a patient's bloodstream could help doctors deliver more personalized treatment for liver cancer, Japanese researchers report.
Spiers, PhD, associate professor in the College of Arts and Sciences' Department of Psychology, traced the origins of the double-trauma amnesia cure belief in a paper for Neurology titled, "The Head Trauma Amnesia Cure: The Making of a Medical Myth."
Watson Pharmaceuticals, Inc. and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million in cash and certain contingent consideration.
› Verified 7 days ago